MedWatch

A part of Watch Media

Novo Holdings and CEO Kutay on the hunt for billion kroner investment

Major Danish holding company is on the lookout for next major investment, but on the side, Novo Holdings has managed to get a few good deals out of the Covid-19 crisis.

Photo: Kenneth Lysbjerg Koustrup/Ritzau Scanpix

BY BENJAMIN WERNER CHRISTENSEN, FINANS, TRANSLATED BY NIELSINE NIELSEN

He is determined to carry out several large billion kroner deals, but the task of finding two or three new billion kroner agreements seems to be drawing out.

The opportunities are few and far between and the valuations are at the high end of the scale.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

  1. Top news from MedWatch this week
  2. Hearing firms urge FDA to increase OTC safety requirements
  3. Danish bank cuts Genmab price target, retains "buy" recommendation
  4. Audientes ships first hearing aid batch to India
  5. Coloplast initiates trial of ostomy leakage product
  6. Novo Nordisk launches oral semaglutide in India
  7. Zealand Pharma finds all patients for phase III study
  8. Leo Pharma's Boston boss exits company
  9. Danish bank expects slow start to 2022 for Coloplast, lowers price target
  10. Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook
  11. Overwhelming majority passes new EMA powers
  12. Hearing aid industry association responds to FDA's proposed OTC regulation
  13. Leo Pharma ends Boston bet
  14. WSA merges with its independent retailer
  15. Layoffs and restructuring will prepare Leo Pharma for IPO

Jobs

See all jobs

See all jobs